期刊
CHEST
卷 153, 期 3, 页码 744-755出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.chest.2017.06.011
关键词
phenotyping; sleep apnea; sleep-disordered breathing; sleep medicine; upper airway
资金
- NeuroSleep National Health and Medical Research Council of Australia Centre of Research Excellence Fellowships [1060992]
- National Health and Medical Research Council of Australia Senior Research Fellowship [1116942]
OSA is a heterogeneous disorder. If left untreated, it has major health, safety, and economic consequences. In addition to varying levels of impairment in pharyngeal anatomy (narrow/collapsible airway), nonanatomical phenotypic traits are also important contributors to OSA for most patients. However, the majority of existing therapies (eg, CPAP, oral appliances, weight loss, positional therapy, upper airway surgery) target only the anatomical cause. These are typically administered as monotherapy according to a trial and error management approach in which the majority of patients are first prescribed CPAP. Despite its high efficacy, CPAP adherence remains unacceptably low, and second-line therapies have variable and unpredictable efficacies. Recent advances in knowledge regarding the multiple causes of OSA using respiratory phenotyping techniques have identified new targets or treatable traits to direct therapy. Identification of the traits and development of therapies that selectively target one or more of the treatable traits has the potential to personalize the management of this chronic health condition to optimize patient outcomes according to precision medicine principles. This brief review highlights the latest developments and emerging therapies for personalized management approaches for OSA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据